Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial

NCT02429193 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02429193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02429193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2016
Completion date
September 1, 2019
Enrollment
16 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer